SEARCH

SEARCH BY CITATION

References

  • 1
    Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951;27:277301.
  • 2
    Jennette J, Falk R, Bacon P, Basu N, Cid M, Ferrario F et al. 2012 Revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2012; Oct 8 [Epub ahead of print].
  • 3
    Sinico RA, Di Toma L, Maggiore U, Tosoni C, Bottero P, Sabadini E et al. Renal involvement in Churg–Strauss syndrome. Am J Kidney Dis 2006;47:770779.
  • 4
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187192.
  • 5
    Dallos T, Heiland GR, Strehl J, Karonitsch T, Gross WL, Moosig F et al. CCL17/thymus and activation-related chemokine in Churg–Strauss syndrome. Arthritis Rheum 2010;62:34963503.
  • 6
    Terrier B, Bieche I, Maisonobe T, Laurendeau I, Rosenzwajg M, Kahn JE et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg–Strauss syndrome. Blood 2010;116:45234531.
  • 7
    Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A et al. HLA-DRB4 as a genetic risk factor for Churg–Strauss syndrome. Arthritis Rheum 2007;56:31593166.
  • 8
    Wieczorek S, Hellmich B, Gross WL, Epplen JT. Associations of Churg–Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al. Arthritis Rheum 2008;58:329330.
  • 9
    Buzio C, Oliva E. Diagnosis of Churg–Strauss syndrome: eotaxin-3 makes it easier. Rheumatology (Oxford) 2011;50:17371738.
  • 10
    Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011;90:1927.
  • 11
    Zwerina J, Bach C, Martorana D, Jatzwauk M, Hegasy G, Moosig F et al. Eotaxin-3 in Churg–Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford) 2011;50:18231827.
  • 12
    Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg–Strauss syndrome. Ann Rheum Dis 2006;65:557559.
  • 13
    Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg–Strauss syndrome. Medicine (Baltimore) 1984;63:6581.
  • 14
    Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP et al. The American College of Rheumatology 1990 criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:10941100.
  • 15
    Watts RA, Lane S, Scott DG. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol 2005;19:191207.
  • 16
    Herlyn K, Hellmich B, Gross WL, Reinhold-Keller E. Stable incidence of systemic vasculitides in schleswig-holstein, Germany. Dtsch Arztebl Int 2008;105:355361.
  • 17
    Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg–Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004;51:9299.
  • 18
    Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg–Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007;46:13291337.
  • 19
    Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2012; Aug 11 [Epub ahead of print].
  • 20
    Zwerina J, Eger G, Englbrecht M, Manger B, Schett G. Churg–Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Semin Arthritis Rheum 2009;39:108115.
  • 21
    Piram M, Maldini C, Mahr A. Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. Curr Opin Rheumatol 2012;24:193200.
  • 22
    Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg–Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum 2008;58:18391848.
  • 23
    Martorana D, Maritati F, Malerba G, Bonatti F, Alberici F, Oliva E et al. PTPN22 R620W polymorphism in the ANCA-associated vasculitides. Rheumatology (Oxford) 2012;51:805812.
  • 24
    Wieczorek S, Hoffjan S, Chan A, Rey L, Harper L, Fricke H et al. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. Genes Immun 2009;10:591595.
  • 25
    Wieczorek S, Holle JU, Bremer JP, Wibisono D, Moosig F, Fricke H et al. Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener's granulomatosis and Churg–Strauss syndrome. Rheumatology (Oxford) 2010;49:907914.
  • 26
    Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 2003;48:814823.
  • 27
    Hubner C, Dietz A, Stremmel W, Stiehl A, Andrassy H. Macrolide-induced Churg–Strauss syndrome in a patient with atopy. Lancet 1997;350:563.
  • 28
    Lilly CM, Churg A, Lazarovich M, Pauwels R, Hendeles L, Rossenwasser LJ et al. Asthma therapies and Churg–Strauss syndrome. J Allergy Clin Immunol 2002;109:S1S20.
  • 29
    Stirling RG, Chung KF. Leukotriene antagonists and Churg–Strauss syndrome: the smoking gun. Thorax 1999;54:865866.
  • 30
    Josefson D. Asthma drug linked with Churg–Strauss syndrome. BMJ 1997;315:330.
  • 31
    Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg–strauss syndrome in patients treated with omalizumab. Chest 2009;136:507518.
  • 32
    Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL et al. The leucotriene receptor antagonist montelukast and the risk of Churg–Strauss syndrome: a case-crossover study. Thorax 2008;63:677682.
  • 33
    Bibby S, Healy B, Steele R, Kumareswaran K, Nelson H, Beasley R. Association between leukotriene receptor antagonist therapy and Churg–Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010;65:132138.
  • 34
    Muschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B et al. Involvement of soluble CD95 in Churg–Strauss syndrome. Am J Pathol 1999;155:915925.
  • 35
    Kiene M, Csernok E, Muller A, Metzler C, Trabandt A, Gross WL. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg–Strauss syndrome. Arthritis Rheum 2001;44:469473.
  • 36
    Jakiela B, Szczeklik W, Plutecka H, Sokolowska B, Mastalerz L, Sanak M et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients. Rheumatology (Oxford) 2012;51:18871893.
  • 37
    Jakiela B, Sanak M, Szczeklik W, Sokolowska B, Plutecka H, Mastalerz L et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg–Strauss syndrome. Clin Exp Rheumatol 2011;29(1 Suppl 64):S23S34.
  • 38
    Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg–Strauss syndrome. Ann Intern Med 2011;155:341343.
  • 39
    Khoury P, Zagallo P, Talar-Williams C, Santos CS, Dinerman E, Holland NC et al. Serum biomarkers are similar in Churg–Strauss syndrome and hypereosinophilic syndrome. Allergy 2012;67:11491156.
  • 40
    Tsurikisawa N, Saito H, Tsuburai T, Oshikata C, Ono E, Mitomi H et al. Differences in regulatory T cells between Churg–Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 2008;122:610616.
  • 41
    Polzer K, Karonitsch T, Neumann T, Eger G, Haberler C, Soleiman A et al. Eotaxin-3 is involved in Churg–Strauss syndrome–a serum marker closely correlating with disease activity. Rheumatology (Oxford) 2008;47:804808.
  • 42
    Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg–Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011;26:28652871.
  • 43
    Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D et al. Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008;47:11041105.
  • 44
    Vaglio A, Strehl JD, Manger B, Maritati F, Alberici F, Beyer C et al. IgG4 immune response in Churg–Strauss syndrome. Ann Rheum Dis 2012;71:390393.
  • 45
    Vaglio A, Casazza I, Grasselli C, Corradi D, Sinico RA, Buzio C. Churg–Strauss syndrome. Kidney Int 2009;76:10061011.
  • 46
    Noth I, Strek ME, Leff AR. Churg–Strauss syndrome. Lancet 2003;361:587594.
  • 47
    Lie JT. Limited forms of Churg–Strauss syndrome. Pathol Annu 1993;28(Pt 2):199220.
  • 48
    Bottero P, Bonini M, Vecchio F, Grittini A, Patruno GM, Colombo B et al. The common allergens in the Churg–Strauss syndrome. Allergy 2007;62:12881294.
  • 49
    Bacciu A, Bacciu S, Mercante G, Ingegnoli F, Grasselli C, Vaglio A et al. Ear, nose and throat manifestations of Churg–Strauss syndrome. Acta Otolaryngol 2006;126:503509.
  • 50
    Bacciu A, Buzio C, Giordano D, Pasanisi E, Vincenti V, Mercante G et al. Nasal polyposis in Churg–Strauss syndrome. Laryngoscope 2008;118:325329.
  • 51
    Keogh KA, Specks U. Churg–Strauss syndrome. Semin Respir Crit Care Med 2006;27:148157.
  • 52
    Kim YK, Lee KS, Chung MP, Han J, Chong S, Chung MJ et al. Pulmonary involvement in Churg–Strauss syndrome: an analysis of CT, clinical, and pathologic findings. Eur Radiol 2007;17:31573165.
  • 53
    Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg–Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:2637.
  • 54
    Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg–Strauss syndrome. Arthritis Rheum 2005;52:29262935.
  • 55
    Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O et al. Prognostic factors in polyarteritis nodosa and Churg–Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:1728.
  • 56
    Neumann T, Manger B, Schmid M, Kroegel C, Hansch A, Kaiser WA et al. Cardiac involvement in Churg–Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009;88:236243.
  • 57
    Dennert RM, van Paassen P, Schalla S, Kuznetsova T, Alzand BS, Staessen JA et al. Cardiac involvement in Churg–Strauss syndrome. Arthritis Rheum 2010;62:627634.
  • 58
    Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillevin L. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009;68:564567.
  • 59
    Vaglio A, Corradi D, Ronda N, Garini G, Buzio C. Large bowel obstruction heralding Churg–Strauss syndrome. Am J Gastroenterol 2004;99:562563.
    Direct Link:
  • 60
    Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D et al. Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann Intern Med 2005;143:632638.
  • 61
    Sironen RK, Seppa A, Kosma VM, Kuopio T. Churg–Strauss syndrome manifested by appendicitis, cholecystitis and superficial micronodular liver lesions–an unusual clinicopathological presentation. J Clin Pathol 2010;63:848850.
  • 62
    Keogh KA, Specks U. Churg–Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003;115:284290.
  • 63
    Cattaneo L, Chierici E, Pavone L, Grasselli C, Manganelli P, Buzio C et al. Peripheral neuropathy in Wegener's granulomatosis, Churg–Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry 2007;78:11191123.
  • 64
    Hattori N, Ichimura M, Nagamatsu M, Li M, Yamamoto K, Kumazawa K et al. Clinicopathological features of Churg–Strauss syndrome-associated neuropathy. Brain 1999;122(Pt 3):427439.
  • 65
    Healy B, Bibby S, Steele R, Weatherall M, Nelson H, Beasley R. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg–Strauss syndrome. J Allergy Clin Immunol 2012; Aug 21 [Epub ahead of print].
  • 66
    Pagnoux C, Guilpain P, Guillevin L. Churg–Strauss syndrome. Curr Opin Rheumatol 2007;19:2532.
  • 67
    Zwerina J, Axmann R, Manger B, Schett G. The emergence of antineutrophil cytoplasmic antibodies may precede the clinical onset of Churg–Strauss syndrome. Arthritis Rheum 2009;60:626627.
  • 68
    Simon HU, Rothenberg ME, Bochner BS, Weller PF, Wardlaw AJ, Wechsler ME et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010;126:4549.
  • 69
    Gotlib J. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:903914.
  • 70
    Corradi D, Vaglio A, Maestri R, Legname V, Leonardi G, Bartoloni G et al. Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. Hum Pathol 2004;35:11601163.
  • 71
    Sinico RA, Bottero P. Churg–Strauss angiitis. Best Pract Res Clin Rheumatol 2009;23:355366.
  • 72
    Wechsler ME. Pulmonary eosinophilic syndromes. Immunol Allergy Clin North Am 2007;27:477492.
  • 73
    Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012;366:539551.
  • 74
    Vaglio A, Zwerina J. IgG4-related disease. N Engl J Med 2012;366:1646; author reply 1646–1647.
  • 75
    Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, Le Guern V et al. Churg–Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007;57:686693.
  • 76
    Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Lauque D et al. Treatment of Churg–Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008;58:586594.
  • 77
    Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg–Strauss syndrome–successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004;22(6 Suppl 36):S52S61.
  • 78
    Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg–Strauss Syndrome. Clin Exp Rheumatol 2012;30:S6265.
  • 79
    Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann Rheum Dis 2004;63:16491654.
  • 80
    Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg–Strauss syndrome. Ann Intern Med 1998;129:370374.
  • 81
    Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg–Strauss syndrome. Clin Exp Rheumatol 2008;26(3 Suppl 49):S35S40.
  • 82
    Metzler C, Csernok E, Gross WL, Hellmich B. Interferon-alpha for maintenance of remission in Churg–Strauss syndrome: a long-term observational study. Clin Exp Rheumatol 2010;28(1 Suppl 57):2430.
  • 83
    Corren J. Anti-interleukin-5 antibody therapy in asthma and allergies. Curr Opin Allergy Clin Immunol 2011;11:565570.
  • 84
    Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F et al. Sustained response to mepolizumab in refractory Churg–Strauss syndrome. J Allergy Clin Immunol 2010;125:267270.
  • 85
    Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg–Strauss syndrome. J Allergy Clin Immunol 2010;125:13361343.
  • 86
    Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:21562168.